Naurex Inc.

33 articles about Naurex Inc.

• Naurex Inc. Announces Initiation of Phase I Trial for Second-Generation Novel Antidepressant Agent NRX-1074

  6/4/2013

• Naurex Inc. Completes $38 Million Series B Financing

  12/17/2012

• Naurex Inc. Release: Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours

  12/6/2012

• Naurex Inc.'s Novel Antidepressant GLYX-13 Recognized as One of Windhover Information Inc.'s 2011 Top 10 Neuroscience Projects to Watch

  11/7/2011

• Naurex Inc. Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression

  6/21/2011

• Naurex Inc. Raises $18 Million to Advance Novel Antidepressant

  5/11/2011

• New Preclinical Data Confirm Naurex Inc.'s Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine

  12/7/2010

• Naurex Inc.: Preclinical Data at Neuroscience 2010 Show Naurex's Novel Antidepressant GLYX-13 Shares Key Efficacy Mechanisms with Ketamine

  11/17/2010

• Naurex Inc.'s Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch

  8/31/2010

• Naurex Inc. Presents Positive Clinical Data On Novel Mechanism Antidepressant Candidate Glyx-13 At Ncdeu 50th Anniversary Meeting

  6/17/2010

• Naurex Inc. Presents Positive Clinical Data on Novel Mechanism Antidepressant Candidate GLYX-13 at NCDEU 50th Anniversary Meeting

  6/17/2010

• Naurex Inc. Reports Positive Top-Line Phase I Results for Its Novel Mechanism NMDA Receptor Modulator GLYX-13 in Treatment-Resistant Depression

  2/10/2010

• Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects

  12/16/2009